Boston Scientific Corporation $BSX Stake Lowered by Korea Investment CORP

Korea Investment CORP decreased its stake in Boston Scientific Corporation (NYSE:BSX) by 8.7% during the 2nd quarter, HoldingsChannel reports. The firm owned 1,462,711 shares of the medical equipment provider’s stock after selling 139,401 shares during the period. Korea Investment CORP’s holdings in Boston Scientific were worth $157,110,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also modified their holdings of BSX. GAMMA Investing LLC increased its holdings in shares of Boston Scientific by 15.4% during the second quarter. GAMMA Investing LLC now owns 29,486 shares of the medical equipment provider’s stock valued at $3,167,000 after purchasing an additional 3,932 shares during the period. MRA Advisory Group acquired a new stake in Boston Scientific during the second quarter valued at approximately $273,000. Bank of New Hampshire boosted its stake in shares of Boston Scientific by 552.0% during the 2nd quarter. Bank of New Hampshire now owns 19,724 shares of the medical equipment provider’s stock worth $2,119,000 after acquiring an additional 16,699 shares in the last quarter. NS Partners Ltd boosted its position in shares of Boston Scientific by 1.6% in the 1st quarter. NS Partners Ltd now owns 368,189 shares of the medical equipment provider’s stock valued at $37,143,000 after purchasing an additional 5,704 shares during the period. Finally, New England Research & Management Inc. purchased a new position in shares of Boston Scientific in the second quarter worth approximately $1,133,000. Institutional investors own 89.07% of the company’s stock.

Boston Scientific Trading Down 0.2%

Shares of BSX opened at $101.14 on Thursday. The stock’s 50-day moving average price is $99.04 and its 200 day moving average price is $102.29. The company has a quick ratio of 0.82, a current ratio of 1.37 and a debt-to-equity ratio of 0.49. The firm has a market capitalization of $149.93 billion, a price-to-earnings ratio of 54.08, a P/E/G ratio of 2.02 and a beta of 0.58. Boston Scientific Corporation has a 12-month low of $85.98 and a 12-month high of $109.50.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings data on Wednesday, October 22nd. The medical equipment provider reported $0.75 EPS for the quarter, topping analysts’ consensus estimates of $0.71 by $0.04. The company had revenue of $5.07 billion during the quarter, compared to the consensus estimate of $4.97 billion. Boston Scientific had a return on equity of 19.74% and a net margin of 14.43%.The company’s quarterly revenue was up 20.3% on a year-over-year basis. During the same quarter last year, the company earned $0.63 EPS. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS. Q4 2025 guidance at 0.770-0.790 EPS. As a group, research analysts predict that Boston Scientific Corporation will post 2.85 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of brokerages have commented on BSX. Barclays raised their price objective on Boston Scientific from $133.00 to $136.00 and gave the stock an “overweight” rating in a research report on Thursday, October 2nd. Morgan Stanley raised their target price on Boston Scientific from $125.00 to $130.00 and gave the company an “overweight” rating in a report on Thursday, October 23rd. Robert W. Baird increased their price objective on Boston Scientific from $123.00 to $128.00 and gave the company an “outperform” rating in a report on Wednesday, October 1st. Evercore ISI restated an “outperform” rating on shares of Boston Scientific in a report on Wednesday, October 22nd. Finally, Oppenheimer upgraded shares of Boston Scientific from a “market perform” rating to an “outperform” rating and boosted their price objective for the stock from $118.00 to $125.00 in a research note on Monday, September 8th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and two have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $123.77.

Insiders Place Their Bets

In other Boston Scientific news, Director Ellen M. Zane sold 12,891 shares of the business’s stock in a transaction on Thursday, November 6th. The shares were sold at an average price of $98.28, for a total value of $1,266,927.48. Following the sale, the director owned 24,134 shares of the company’s stock, valued at $2,371,889.52. The trade was a 34.82% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, EVP Joseph Michael Fitzgerald sold 50,000 shares of the stock in a transaction dated Monday, November 3rd. The stock was sold at an average price of $99.47, for a total transaction of $4,973,500.00. Following the completion of the transaction, the executive vice president directly owned 178,342 shares of the company’s stock, valued at $17,739,678.74. This trade represents a 21.90% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 175,782 shares of company stock worth $17,742,314 in the last quarter. Corporate insiders own 0.50% of the company’s stock.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.